CIP2A, cellular inhibitor of PP2A, 57650

N. diseases: 141; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3642347
Disease: Basal-Like Breast Carcinoma
Basal-Like Breast Carcinoma 		0.010 Biomarker disease BEFREE Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. 19036157 2008
CUI: C3714756
Disease: Intellectual Disability
Intellectual Disability 		0.010 GeneticVariation group BEFREE Whole exome sequencing in Dandy-Walker variant with intellectual disability reveals an activating CIP2A mutation as novel genetic cause. 29846820 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.040 Biomarker disease BEFREE Whether Genistein can ameliorate AD pathology through targeting CIP2A needs further investigation. 31470788 2019
CUI: C1843013
Disease: Alzheimer disease, familial, type 3
Alzheimer disease, familial, type 3 		0.010 Biomarker disease BEFREE Whether Genistein can ameliorate AD pathology through targeting CIP2A needs further investigation. 31470788 2019
CUI: C1704272
Disease: Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia 		0.030 Biomarker disease BEFREE When a selected panel of six TAAs including p90 were used for immunoscreening, the cumulative positive reactions in prostate cancer sera reached 92.5%, significantly higher than in BPH and other control sera. 15538718 2005
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.070 AlteredExpression disease BEFREE We thus assessed whether CIP2A expression is associated with sensitivity of GC to DDP. 29103022 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.070 AlteredExpression disease BEFREE We thus assessed whether CIP2A expression is associated with sensitivity of GC to DDP. 29103022 2018
CUI: C0025202
Disease: melanoma
melanoma 		0.030 Biomarker disease BEFREE We then used the Dual-Luciferase assay system, quantitative real-time RT-PCR (qRT-PCR), and Western blot analysis to determine that miR-218 targeted the 3'-UTR of the oncogenes CIP2A and BMI1 and thus regulated the biological process of melanoma. 24839010 2014
CUI: C0036857
Disease: Severe intellectual disability
Severe intellectual disability 		0.010 GeneticVariation disease BEFREE We report a novel heterozygous CIP2A p.D269V mutation via whole exome sequencing in two siblings with DWV and severe intellectual disability who were born to non-consanguineous parents. 29846820 2018
CUI: C2931015
Disease: Dandy Walker variant
Dandy Walker variant 		0.010 GeneticVariation disease BEFREE We report a novel heterozygous CIP2A p.D269V mutation via whole exome sequencing in two siblings with DWV and severe intellectual disability who were born to non-consanguineous parents. 29846820 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 Biomarker phenotype BEFREE We previously demonstrated that p90 ribosomal S6 kinase 2 (RSK2) promotes tumor metastasis. 27041561 2016
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.020 Biomarker group BEFREE We previously demonstrated that p90 ribosomal S6 kinase 2 (RSK2) promotes tumor metastasis. 27041561 2016
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.060 Biomarker disease BEFREE We investigated the role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in the synergism between temsirolimus and cetuximab in colon cancer. 24493623 2014
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.060 Biomarker disease BEFREE We investigated the role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in the synergism between temsirolimus and cetuximab in colon cancer. 24493623 2014
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.020 Biomarker phenotype BEFREE We investigated CIP2A expression and its clinical significance in EGJA and conducted a meta-analysis to explore the relationship between CIP2A and the prognosis of patients with solid tumors. 31534561 2019
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.070 Biomarker disease BEFREE We identified overexpression of the endogenous PP2A inhibitors SET and CIP2A, and downregulation of regulatory PP2A such as PPP2R2A and PPP2R5E, as contributing mechanisms to PP2A inhibition in colorectal cancer. 24448818 2014
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.050 Biomarker disease BEFREE We identified overexpression of the endogenous PP2A inhibitors SET and CIP2A, and downregulation of regulatory PP2A such as PPP2R2A and PPP2R5E, as contributing mechanisms to PP2A inhibition in colorectal cancer. 24448818 2014
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 AlteredExpression group BEFREE We found that CIP2A expression was positively correlated with ATF6 expression by analyzing publicly available RNA sequence data of patients with colorectal cancer (The Cancer Genome Atlas, TCGA). 30063110 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 AlteredExpression group BEFREE We found that CIP2A expression was positively correlated with ATF6 expression by analyzing publicly available RNA sequence data of patients with colorectal cancer (The Cancer Genome Atlas, TCGA). 30063110 2018
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.070 AlteredExpression disease BEFREE We found that CIP2A expression was positively correlated with ATF6 expression by analyzing publicly available RNA sequence data of patients with colorectal cancer (The Cancer Genome Atlas, TCGA). 30063110 2018
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.050 AlteredExpression disease BEFREE We found that CIP2A expression was positively correlated with ATF6 expression by analyzing publicly available RNA sequence data of patients with colorectal cancer (The Cancer Genome Atlas, TCGA). 30063110 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.090 AlteredExpression disease BEFREE We found accumulated cellular senescence in HCC cells with CIP2A knockdown, companying expression changes of senescence associated proteins (p21, CDK2, CDK4, cyclin D1, MCM7 and FoxM1). 29175329 2018
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.050 AlteredExpression disease BEFREE We explored the CIP2A mRNA expression in a publically available database and found that higher levels of CIP2A mRNA is associated with worse recurrence-free survival in patients with TNBC. 28027514 2017
CUI: C4722518
Disease: Triple-Negative Breast Carcinoma
Triple-Negative Breast Carcinoma 		0.040 AlteredExpression disease BEFREE We explored the CIP2A mRNA expression in a publically available database and found that higher levels of CIP2A mRNA is associated with worse recurrence-free survival in patients with TNBC. 28027514 2017
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.080 Biomarker disease BEFREE We describe PP2A inactivation via direct and indirect means and explore the actions of two key PP2A endogenous inhibitors, cancerous inhibitor of PP2A (CIP2A) and inhibitor 2 of PP2A (SET), and the role they play in COPD and LC. 31623614 2019